Our primary objectives were as follows: (1) to identify and characterize the bioactive compounds in SCF and their molecular targets in AD pathology through a network pharmacology analysis; and (2) to validate the therapeutic effects of SCF water extract in an Aβ-induced AD rat model. This evidence concerns the gene KITLG and Alzheimer disease.